Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-127,415
Closed -$6.42M 246
2015
Q4
$6.42M Sell
127,415
-262,113
-67% -$13.2M 0.48% 34
2015
Q3
$18.4M Sell
389,528
-82,892
-18% -$4.4M 0.49% 36
2015
Q2
$25.7M Buy
472,420
+21,539
+5% +$1.21M 0.43% 43
2015
Q1
$24.7M Buy
450,881
+25,983
+6% +$1.47M 0.41% 47
2014
Q4
$23M Buy
424,898
+58,892
+16% +$3.28M 0.39% 52
2014
Q3
$20.7M Buy
366,006
+922
+0.3% +$51.8K 0.37% 58
2014
Q2
$20.2M Buy
365,084
+10,272
+3% +$560K 0.35% 61
2014
Q1
$19.2M Buy
354,812
+205,107
+137% +$10.6M 0.34% 55
2013
Q4
$7.15M Buy
149,705
+4,152
+3% +$190K 0.13% 179
2013
Q3
$6.61M Buy
145,553
+15,897
+12% +$726K 0.12% 173
2013
Q2
$5.75M Buy
+129,656
New +$5.79M 0.1% 184

Other funds holding MRK

Curian Capital's MRK Position: Q1 2016 in Review

Curian Capital sold out of Merck (MRK) in Q1 2016, closing a stake of 127,415 shares — an estimated $6.42M sold.

Curian Capital first reported a position in MRK in Q2 2013 and held it in 11 quarters. The position peaked at $25.7M in Q2 2015. 1,744 funds tracked by Wall St. Rank hold MRK as of Q1 2016.

  • Curian Capital reported no remaining Merck position as of Q1 2016 after selling out during the quarter.
  • Curian Capital sold 127,415 Merck shares in Q1 2016, an estimated $6.42M.
  • Curian Capital first reported a position in Merck in Q2 2013 and held it in 11 quarters.
  • Curian Capital's Merck position peaked at $25.7M in Q2 2015.
  • 1,744 funds tracked by Wall St. Rank held Merck as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.